Sign in Subscribe
Class action lawsuits

Securities Class Action Lawsuit Filed Against Rocket Pharmaceuticals

Strategic Insights

— 1 min read

A class action lawsuit has been filed against Rocket Pharmaceuticals, Inc., alleging that the company made materially false and misleading statements regarding its Phase 2 pivotal trial for RP-A501, an experimental therapy for Danon disease. The lawsuit claims that investors suffered substantial losses after the price of their shares crashed over 60% following the FDA's clinical hold on the trial. Hagens Berman, a global plaintiffs' rights complex litigation firm, is urging investors who suffered losses to contact their attorneys and those with knowledge that may assist the investigation to come forward.

Key Takeaways:

  • The lawsuit alleges that Rocket Pharmaceuticals made false and misleading statements about the trial protocol and safety of RP-A501, including failing to disclose Serious Adverse Events, including patient deaths, and amending the trial protocol without notifying the FDA and investors.
  • The company's stock price crashed 62% on May 27, 2025, after investors learned of the FDA's clinical hold on the trial.
  • Hagens Berman is investigating claims that Rocket Pharmaceuticals may have misled investors and is seeking to represent investors who purchased or otherwise acquired Rocket Pharmaceuticals securities between February 27, 2025 and May 26, 2025.
  • The lead plaintiff deadline to file the lawsuit is August 11, 2025.
  • The SEC Whistleblower program offers rewards of up to 30% for original information that leads to a successful recovery.
  • Hagens Berman has secured over $2.9 billion in corporate accountability cases.

Statistics:

  • The lawsuit covers investors who purchased or otherwise acquired Rocket Pharmaceuticals securities between February 27, 2025 and May 26, 2025.
  • The company's stock price crashed 62% on May 27, 2025, after the FDA's clinical hold on the trial.
  • The lawsuit alleges that Rocket Pharmaceuticals amended the trial protocol without properly disclosing the changes to investors.
  • The SEC Whistleblower program offers rewards of up to 30% for original information that leads to a successful recovery.

Sources:

  • Ho v. Rocket Pharmaceuticals, Inc., et al., No. 3:25-cv-10049 (D. N.J.)
  • GlobeNewswire, "Securities Class Action Lawsuit Filed Against Rocket Pharmaceuticals"
  • Hagens Berman, "Rocket Pharmaceuticals Securities Class Action"
  • SEC Whistleblower Program: whistleblowers.gov

Read more